In this episode of the VJNeurology Podcast, Jeffrey Dunn, MD, Stanford University School of Medicine, Palo Alto, CA, shares insights from a Phase I trial (NCT06138132) of CAR T-cell therapy for multiple sclerosis (MS). CAR T-cell therapy is a form of adoptive cell transfer that has revolutionized hematologic oncology and is now being investigated as a targeted immunotherapeutic approach for autoimmune diseases such as MS. Prof. Dunn will delve into the mechanism of action of CAR-T in MS and share findings from the trial.

In this episode of the VJNeurology Podcast, we’re joined by Krystof Bankiewicz, MD, PhD, The Ohio State University, Columbus, OH, to explore the evolving role of gene therapy in Parkinson’s disease and other neurological disorders. Dr Bankiewicz provides an insightful overview of gene therapies currently in clinical development, highlighting emerging efficacy and safety data from ongoing trials. He also delves into the selection of appropriate candidates for these treatments and discusses how close we are to translating these advances into routine clinical care.

In this podcast episode, leading experts Kara Melmed (NYU Langone Health, New York City, NY) and Chitra Venkatasubramanian (Stanford University,...

Welcome to today’s podcast, which focuses on the understanding and management of rare brain disorders. This episode, in honor of...

The 2024 revision of the McDonald diagnostic criteria for multiple sclerosis (MS) was recently presented at the 40th Congress of...

Dopaminergic medications have been widely used in the treatment of restless legs syndrome (RLS), where they are effective at reducing...

In recent years, genetic therapies have garnered much attention for their potential to modify the underlying pathological processes in neurological...

In this episode, we delve into the complexities of managing status epilepticus, particularly the refractory stages that resist initial treatments....

Medication-overuse headache (MOH) is a neurological disorder, affecting 1% of the general population. It plays a huge role in transforming...

The latest guidelines recommend endovascular thrombectomy (EVT) as the gold standard treatment approach for eligible patients with an acute ischemic...

Over the past decade, a genomic revolution has unfolded in medicine, and the epilepsy space is no exception. The intricacies...

Cluster headache, a rare and severe form of headache disorder, represents the most common trigeminal autonomic cephalalgia. Due to its...

In this podcast, key opinion leaders Hans Lassman, MD, Medical University of Vienna; Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine; Torge Rempe, MD, PhD, University of Florida College of Medicine; and Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, give a comprehensive overview of the current research landscape in MOGAD, including its differentiation from MS, diagnostic techniques, predictors of relapse, and an ongoing clinical trial investigating an interleukin-6 targeted monoclonal antibody in the treatment of relapsing MOGAD.

In this podcast, Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany; Chia-Chun Chiang, MD, Mayo Clinic, Rochester, MN; and Daniel Goldenholz, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, engage in a thought-provoking discussion on the latest developments in AI application. They explore how AI's predictive capabilities could revolutionize basic science, its potential role in the diagnosis and treatment of headache disorders, and the current and prospective uses of AI across different fields of neurology. Join us in this exciting exploration of AI's potential to reshape neurology, its existing successes, and the exciting opportunities it holds for the future.

Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients' neurological conditions. We are joined by leading neurology experts who will share their insights into the diverse applications of wearables in the fields of epilepsy, movement disorders, multiple sclerosis and sleep disorders, offering a glimpse into the future of neurology.

The causative nature of alpha-synuclein (ɑ-syn) accumulation in Parkinson's disease (PD) pathophysiology has been a subject of debate among researchers, ever since its identification in Lewy bodies. In this episode, experts discuss our current understanding of the role of ɑ-syn in PD, as well as the possibility that the loss of normal ɑ-syn function may be more relevant than the accumulation of insoluble ɑ-syn. We will hear from researchers working to improve the diagnosis and monitoring of PD, with the exciting development of novel ɑ-syn-PET tracers and seed amplification assays that can detect early PD with high sensitivity and specificity.

Biomarker development and discovery have been an important point in multiple sclerosis (MS) research for many years. In this podcast, Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD; Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA; and Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, discuss recent updates on the development and validation of biomarkers that can predict disability progression, monitor ongoing disease activity, and assess treatment response.

In this episode, key opinion leaders debate the value of bridging therapy for endovascular thrombectomy following recent reports from several large scale randomized controlled trials. What evidence do we have and what is the best way forward?  With Manon Kappelhof, Johannes Kaesmacher, Urs Fischer, Yvo B. Roos, and Thanh Nguyen.

Narcolepsy is a chronic neurological disorder of rapid onset eye movement (REM) sleep, affecting the sleep-wake cycle in the brain. It is characterized by excessive daytime sleepiness, uncontrollable sleep attacks, and sleep fragmentation and is often associated with cataplexy, sleep paralysis, and hypnagogic hallucinations. In this week’s podcast, Claudio Bassetti, MD, Inselspital, Bern, Switzerland; Emmanuel Mignot, MD, PhD, Stanford University Center for Sleep Sciences, Palo Alto, CA; and Kiran Maski, MD, MPH, Boston Children’s Hospital, Boston, MA, discuss current understanding of narcolepsy and the potential for future treatment interventions. 

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and thus far, only efficacious symptomatic treatments have been developed, with PD remaining a progressive disease without a cure. In this week’s podcast Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA; Daniel Otzen, PhD, Aarhus University,  Aarhus, Denmark; Charbel Moussa, MBBS, PhD,  Georgetown University Medical Center, Washington, D.C.; and Serge Przedborski, MD, PhD, Columbia University Irving Medical Center, New York, NY, discuss novel treatment approaches under investigation for PD.